Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of antibacterials to treat multi-drug resistant (MDR), gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). In addition to plazomicin, the Company�s research and development pipeline includes two programs that specifically target infections caused by Pseudomonas aeruginosa, which it refers to as antipseudomonal programs. The first is a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and the second is a therapeutic antibody program. It is also pursuing small molecule research programs targeting other essential gram-negative enzymes.